Immunomedics, Inc. (IMMU) Q3 2019 Earnings Conference Call October 30, 2019 5:00 PM ET
Company Participants
Chau Cheng - Senior Director of Investor Relations
Behzad Aghazadeh - Executive Chairman
Usama Malik - Chief Financial Officer
Scott Canute - Executive Director
Conference Call Participants
Jim Birchenough - Wells Fargo
Varun Kumar - Cantor Fitzgerald
Paul Choi - Goldman Sachs
Michael Schmidt - Guggenheim
Phil Nadeau - Cowen & Company
Shanshan Xu - Berenberg Capital
Chris Howerton - Jeffrey
Joe Catanzaro - Piper Jaffray
Operator
Good afternoon, ladies and gentlemen, thank you for standing by. As a reminder, this call is being recorded, today is Wednesday, October 30, 2019.
At this time, I would like to turn the conference over to Chau Cheng, Senior Director of Investor Relations at Immunomedics. Thank you.
Chau Cheng
Thank you, John. Before we begin, I would like to remind everyone that during this call, we will be making forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Such statements may involve significant risks and uncertainties and therefore actual results could differ materially from those expressed or implied on this call. The factors that could cause such differences please refer to our regulatory filings with the Securities and Exchange Commission.
With us on the call today with prepared remarks are Dr. Behzad Aghazadeh, Executive Chairman; and Usama Malik, Chief Financial Officer. Also on the call for Q&A is Scott Canute, Executive Director. Following the prepared remarks, we will open the call up for questions. Thank you. Behzad?
Behzad Aghazadeh
Thank you, Chau. Good morning everyone, and thank you for joining us. As noted during our investor event of ESMO. We had a meeting with the FDA in late September to update the agency on our progress and addressing the matters raised in the CRL came alignment on the
- Read more current IMMU analysis and news
- View all earnings call transcripts